Amgen
THOUSAND OAKS, California, June 24, 2011 -
Amgen (NASDAQ: AMGN) today announced that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines
Agency (EMA) has adopted a positive opinion recommending that
Vectibix (panitumumab) be approved for use in the European Union
(EU) in first-line in combination with FOLFOX and in second-line in
combination with FOLFIRI in patients who have received first-line
fluoropyrimidine-based chemotherapy (excluding irinotecan) for
patients with wild-type KRAS metastatic colorectal cancer
(mCRC), following a successful re-examination procedure by
Amgen.
ZUG, Switzerland, June 10, 2011 -
Amgen announced today the results of a new European survey of people
suffering from a rare blood disorder called immune thrombocytopenia (ITP)
shows that one in four feels the impact of the condition on their daily lives
is severe, causing them anxiety and concern.
ZUG, Switzerland, June 10, 2011 -
- Interim Results From Largest Study Of Adult ITP Patients To Date
Amgen today announced interim results from an international, single-arm
study ("209 study") evaluating the safety and efficacy of Nplate(R)
(romiplostim) in adults with primary immune thrombocytopenia (ITP) - a rare
blood disorder - demonstrated that Nplate induced a rapid platelet response
with a good safety profile in adult ITP patients with low platelet counts and
bleeding symptoms (Abstract #0223).
ZUG, Switzerland, June 9, 2011 -
Amgen announced today the launch of its first oncology website for the
international oncology community outside the United States.
THOUSAND OAKS, California, May 20, 2011 - Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency (EMA) has
recommended a positive opinion for the marketing authorization of XGEVA(TM)
(denosumab) for the prevention of skeletal-related events (pathological
fracture, radiation to bone, spinal cord compression or surgery to bone) in
adults with bone metastases from solid tumors.
More News
- Amgen Acquires Privately Held Brazilian Pharmaceutical Company Bergamo and Agrees to Reacquire Rights to Certain Amgen Products in Brazil from Hypermarcas
- Amgen to Appeal CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
- New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate
- Prolia(R) (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
- Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
- Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards
- Results From Study of Vascular Calcification in Dialysis Patients Presented in Late-Breaking Clinical Trial Session at ERA-EDTA 2010 Congress
- New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy
- Given as an Injection Every Six Months, Prolia Reduced the Risk of Fractures in Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fractures
- Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union
- Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
- Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
- Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
- Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
- Amgen Scholars Europe Programme Convenes Undergraduates From 15 Countries for Innovative Science Research
- Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
- New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP
- New Findings Provide Additional Insights into the Management of Anaemia and Secondary Hyperparathyroidism in Chronic Kidney Disease Patients
